SEC Form DEFA14A filed by Nuvation Bio Inc.
$NUVB
Biotechnology: Pharmaceutical Preparations
Health Care
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
Proxy Statement Pursuant to Section 14(a)
of the Securities Exchange Act of 1934
(Amendment No. __)
Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐
Check the appropriate box:
| ☐ |
Preliminary Proxy Statement
|
| ☐ |
Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
|
| ☐ |
Definitive Proxy Statement
|
| ☒ |
Definitive Additional Materials
|
| ☐ |
Soliciting Material Pursuant to §240.14a-12
|
Nuvation Bio Inc.
(Name of Registrant as Specified in its Charter)
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
Payment of Filing Fee (Check all boxes that apply):
| ☒ |
No fee required
|
| ☐ |
Fee paid previously with preliminary materials
|
| ☐ |
Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11
|
Supplement to Definitive Proxy Statement for
2026 Annual Meeting of Stockholders
To Be Held on May 21, 2026
Explanatory Note
This supplement to the proxy statement dated April 21, 2026 (the Supplement) supplements the definitive proxy statement of Nuvation Bio Inc. (the Company) filed with the Securities and Exchange
Commission (the SEC) on April 10, 2026 (the Proxy Statement) in connection with the Company’s 2026 Annual Meeting of Stockholders to be held on May 21, 2026 (the Annual Meeting).
This Supplement is being filed to correct a typographical error contained in the Non-Employee Director Compensation table included on page 20 of the Proxy Statement, which incorrectly reported the
cash compensation paid to Robert Mashal, M.D. as $37,500. The correct amount of cash compensation paid to Robert Mashal, M.D. is $47,500, which also results in a change to Dr. Mashal’s total compensation amount. Accordingly, the Proxy Statement
disclosure under the heading “Non-Employee Director Compensation” is amended and replaced in its entirety with the following disclosure.
Non-Employee Director Compensation
The following table sets forth information concerning the compensation earned by our non-employee directors during the fiscal year ended December 31, 2025:
|
Name
|
Fees
Earned
or Paid
in Cash
|
Option
Awards(1)
|
Total
|
||||||||||
|
Robert B. Bazemore, Jr.
|
$
|
98,000
|
$
|
385,000
|
$
|
483,000
|
|||||||
|
Kim Blickenstaff
|
$
|
51,250
|
$
|
385,000
|
$
|
436,250
|
|||||||
|
Min Cui, Ph.D.(2)
|
—
|
—
|
—
|
||||||||||
|
Kathryn E. Falberg
|
$
|
60,000
|
$
|
385,000
|
$
|
445,000
|
|||||||
|
Robert Mashal, M.D.
|
$
|
47,500
|
$
|
385,000
|
$
|
432,500
|
|||||||
|
W. Anthony Vernon
|
$
|
61,000
|
$
|
385,000
|
$
|
446,000
|
|||||||
| (1) |
The amounts in this column reflect the aggregate grant date fair value of each option award granted during the fiscal year, computed in accordance with FASB ASC Topic 718. The valuation assumptions used in
determining such amounts are described in Note 12 to our financial statements included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025. As of December 31, 2025, each of our then-serving non-employee directors
held options to purchase an aggregate of 292,983 shares of our Class A Stock, other than Dr. Cui who held no options to purchase shares of our capital stock and Dr. Mashal who held options to purchase an aggregate of 560,632 shares of our Class A Stock.
|
| (2) |
Dr. Cui voluntarily forfeited the retainer and the option awards granted to him during the fiscal year.
|
Except for the corrections described above, no other changes have been made to the Proxy Statement. This Supplement should be read in conjunction with the Proxy Statement, which is available free
of charge on the SEC's website at www.sec.gov and on the Company’s website at investors.nuvationbio.com. The Company urges stockholders to read the Proxy Statement, this Supplement, and any other relevant documents filed with the SEC when they
become available, as they contain important information. From and after the date of this Supplement, any references to the “Proxy Statement” are to the Proxy Statement as supplemented hereby.